Akseli Hemminki

52PUBLICATIONS
61CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesPredictive and prognostic markersMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (52)

|Aug 20, 2026
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

|Feb 26, 2026
Increase in second primary lung cancers in a nation-wide cohort study from Sweden.

Frantisek Zitricky, Kristina Sundquist, Jan Sundquist

|Nov 29, 2025
Second Primary Lung Cancer Associated With Family History of Lung Cancer.

Frantisek Zitricky, Kristina Sundquist, Jan Sundquist

|Apr 10, 2025
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.

Tatiana V Kudling, Dmitrii Bychkov, James H A Clubb

|Mar 29, 2025
Sex specific familial risk in lung cancer through changing histologies in Sweden.

Kari Hemminki, Frantisek Zitricky, Kristina Sundquist

|Feb 05, 2025
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.

Matthew Stephen Block, James Hugo Armstrong Clubb, Johanna Mäenpää

Pageof 9

Frequent Collaborators

29 joint publications

Kari Hemminki

13 joint publications

Asta Försti

8 joint publications

Santeri Pakola

8 joint publications

Guoqiao Zheng